RxSight's fair value estimate has shifted only slightly, moving from about US$9.89 to around US$10.33 per share, as analysts factor in a quarter they describe as better than feared, with revenue of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback